Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06542159
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-04
Brief Title:
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases a Prospective Randomized Controlled Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to explore the safety and efficacy of eliminating the PTV planning target volume margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer NSCLC or pulmonary oligometastases
Detailed Description:
This study aims to explore the safety and efficacy of eliminating the PTV expansion margin based on online adaptive stereotactic body radiotherapy SBRT for early-stage non-small cell lung cancer NSCLC or pulmonary oligometastases In this study patients will be stratified according to whether they have primary early-stage NSCLC then randomly assigned in a 11 ratio to the study group or the control group Patients in the study group will receive online adaptive SBRT without PTV expansion margin while patients in the control group will receive conventional standard SBRT After the completion of treatment patients will be followed up regularly to assess safety and efficacy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None